Ticker
ABBV

Price
139.33
Stock movement up
+1.42 (1.03%)
Company name
AbbVie Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
246.21B
Ent value
367.01B
Price/Sales
4.34
Price/Book
15.12
Div yield
4.05%
Div growth
17.93%
Growth years
9
FCF payout
42.93%
Trailing P/E
19.73
Forward P/E
11.63
PEG
2.39
EPS growth
36.80%
1 year return
15.72%
3 year return
27.99%
5 year return
14.27%
10 year return
-
Last updated: 2022-08-25

BUSINESS INSIGHT

Revenues per Product Category ($M)

Loading...

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share5.64
Dividend yield4.05%
Payout frequencyQuarterly
Maximum yield7.32%
Average yield4.66%
Minimum yield2.77%
Discount to avg yield-15.08%
Upside potential-13.10%
Yield as % of max yield55.32%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield4.05%
Current yield distribution71.90%
Yield at 100% (Min)2.77%
Yield at 90%3.42%
Yield at 80%3.83%
Yield at 50% (Median)4.80%
Yield at 20%5.39%
Yield at 10%5.77%
Yield at 0% (Max)7.32%

Dividend per share

Loading...
Dividend per share data
Years of growth9 years
CCC statusDividend Challenger
Dividend per share5.64
Payout frequencyQuarterly
Ex-div date14 Jul 2022
EPS (TTM)7.02
EPS (1y forward)11.98
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
ABBVS&P500
DGR MR8.46%15.44%
DGR TTM8.86%7.80%
DGR 3 years13.15%3.88%
DGR 5 years17.93%4.73%
DGR 10 years-8.30%
DGR 15 years-5.82%
Time since last change announced332 days
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM75.85%42.93%
Average--
Forward47.08%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E19.73
Price to OCF10.79
Price to FCF11.17
Price to EBITDA9.96
EV to EBITDA14.84

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.34
Price to Book15.12
EV to Sales6.47

FINANCIALS

Per share

Loading...
Per share data
Current share count1.77B
EPS (TTM)7.02
FCF per share (TTM)12.40

Income statement

Loading...
Income statement data
Revenue (TTM)56.73B
Gross profit (TTM)39.44B
Operating income (TTM)18.68B
Net income (TTM)12.48B
EPS (TTM)7.02
EPS (1y forward)11.98

Margins

Loading...
Margins data
Gross margin (TTM)69.53%
Operating margin (TTM)32.94%
Profit margin (TTM)22.00%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash6.10B
Net receivables10.73B
Total current assets26.51B
Goodwill32.30B
Intangible assets73.99B
Property, plant and equipment0.00
Total assets143.21B
Accounts payable22.57B
Short/Current long term debt73.47B
Total current liabilities32.52B
Total liabilities126.90B
Shareholder's equity16.28B
Net tangible assets-92.92B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)22.81B
Capital expenditures (TTM)761.00M
Free cash flow (TTM)22.05B
Dividends paid (TTM)9.46B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity76.64%
Return on Assets8.71%
Return on Invested Capital47.57%
Cash Return on Invested Capital84.04%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open138.77
Daily high139.56
Daily low137.67
Daily Volume3.30M
All-time high174.96
1y analyst estimate162.58
Beta0.75
EPS (TTM)7.02
Dividend per share5.64
Ex-div date14 Jul 2022
Next earnings date27 Oct 2022

Downside potential

Loading...
Downside potential data
ABBVS&P500
Current price drop from All-time high-20.36%-12.18%
Highest price drop-48.88%-56.47%
Date of highest drop15 Aug 20199 Mar 2009
Avg drop from high-14.22%-11.38%
Avg time to new high17 days12 days
Max time to new high975 days1805 days
COMPANY DETAILS
ABBV (AbbVie Inc) company logo
Marketcap
246.21B
Marketcap category
Large-cap
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees
50000
SEC filings
CEO
Richard Gonzalez
Country
USA
City
North Chicago
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
A little-known group of Buffett stocks includes three members of dividend royalty with solid growth prospects.
September 25, 2022
With a price-to-earnings (or "P/E") ratio of 20.1x AbbVie Inc. ( NYSE:ABBV ) may be sending bearish signals at the...
September 24, 2022
Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. AbbVie last reported its earnings in July. Humira remains key to AbbVie's ...
September 24, 2022
From biotech to managed care, companies are tackling new challenges in science and business. Our healthcare roundtable experts pick 12 stocks that could win.
September 23, 2022
Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). AbbVie is one of the largest pharmaceutical companies around. Like ot...
September 23, 2022
As one of the world's largest pharmaceutical companies, it's no surprise to hear that AbbVie (NYSE: ABBV) has plenty of moving parts for investors to think about when they're wondering what to do to m...
September 23, 2022
AbbVie recently submitted a regulatory application in the European Union for Rinvoq to treat patients with a form of inflammatory bowel disease.
September 23, 2022
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), and skinbetter science® announce a new report from their DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative®, along with a long-...
September 22, 2022
One good way to start your search is by looking at Dividend Kings. AbbVie (NYSE: ABBV) sells the biggest blockbuster of all time. AbbVie's two other immunology drugs -- Skyrizi and Rinvoq -- togethe...
September 22, 2022
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
September 21, 2022
Next page